donanemab-azbt

Master Formulation Record

To minimize adverse reactions when administering Donanemab-azbt (Kisunla), follow these evidence-based protocols:Pre-Infusion PreparationBaseline Assessments:Perform APOE ε4 genotyping (higher ARIA risk in homozygotes).Obtain a brain MRI....

The criteria for stopping Donanemab-azbt (Kisunla) therapy are primarily based on amyloid plaque reduction and safety monitoring, as outlined in clinical guidelines and prescribing information:Primary....